<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>bioAffinity Technologies, Inc. ( (BIAF) ) has issued an announcement. On May 12, 2026, bioAffinity Technologies reported that unit sales of its CyPath® Lung diagnostic test reached a record monthly level and rose nearly 300% in April 2026 versus April 2025, based on preliminary unaudited data. Management said the surge has exceeded internal expectations, citing accelerating physician adoption and broader clinical integration of the noninvasive test to aid in lung cancer diagnosis and pulmonary nodule management. The company attributed the growth to an expansion in ordering physician sites, increased peer-to-peer education among pulmonologists and workflow integration of CyPath® Lung for risk assessment and nodule management. It is also advancing a large-scale longitudinal study to generate further validation data, expanding use of CyPath® Lung in monitoring lung cancer survivors and developing additional diagnostics for asthma and COPD, underscoring a strategy to scale its technology platform and deepen its presence in respiratory disease diagnostics. Spark’s Take on BIAF Stock According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral. The score is held down primarily by weak financial performance (widening losses and higher cash burn) and a soft technical setup (negative MACD and price below key moving averages). Corporate events provide some offset via improving product adoption signals and expanded clinical validation efforts, while valuation remains constrained by negative earnings and no dividend support. To see Spark’s full report on BIAF stock, click here. More about bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics and early cancer detection, targeting diseases of the lung and broad-spectrum cancer treatments. Its lead product, CyPath® Lung, is a laboratory-developed test marketed through subsidiary Precision Pathology Laboratory Services under CLIA oversight and is designed to detect early-stage lung cancer in high-risk patients using flow cytometry and AI-based analysis of sputum samples. In clinical evaluation, CyPath® Lung has demonstrated high performance metrics, including 92% sensitivity, 87% specificity, 88% overall accuracy and a 99% negative predictive value in high-risk patients with small indeterminate nodules under 20 millimeters. The test is intended to be used alongside other clinical information to support lung cancer risk stratification and nodule management while helping reduce unnecessary invasive procedures for patients with negative results. Average Trading Volume: 8,967,836 Technical Sentiment Signal: Sell Current Market Cap: $9.13M Find detailed analytics on BIAF stock on TipRanks’ Stock Analysis page.</div>

BIAF

SBIO

LABU

bioAffinity Technologies, Inc. reported a nearly 300% increase in unit sales of its CyPath® Lung diagnostic test in April 2026 compared to April 2025, driven by greater physician adoption and clinical integration. The company is expanding its technology platform and conducting a longitudinal study for further validation. However, Spark's AI Analyst rates BIAF stock as Neutral due to weak financial performance and a soft technical setup, despite improving product adoption signals. bioAffinity focuses on noninvasive diagnostics for lung diseases and early cancer detection, with CyPath® Lung showing high performance metrics in clinical evaluations.

bioAffinity CyPath Lung Test Sales Surge Sharply